Related Experiment Videos
Converting enzyme inhibition: implications for renal perfusion and function
Clinical and Experimental Pharmacology & Physiology. Supplement
|January 1, 1982
Summary
Converting enzyme inhibitors show renal benefits in hypertension and heart failure. However, whether this stems from reduced angiotensin II or other actions remains unclear, requiring further investigation.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Angiotensin is implicated in renal perfusion and function.
- Evidence suggests intrarenal actions of angiotensin may be evolutionarily older.
- Systemic and adrenal actions arose later in phylogeny.
Purpose of the Study:
- To investigate the renal vascular response to converting enzyme inhibitors.
- To explore the mechanisms underlying these responses in essential hypertension and congestive heart failure.
Main Methods:
- Administration of teprotide and captopril.
- Observation of renal vascular response, sodium excretion, and glomerular filtration rate.
- Comparison with angiotensin antagonists in animal models and human patients.
Main Results:
- Converting enzyme inhibitors induced potentiated renal vascular response, increased sodium excretion, and occasional GFR increase in hypertensive patients.
- Similar responses were observed in heart failure patients resistant to other vasodilators.
- Rigorous evidence for the specific mechanism (angiotensin II reduction vs. other actions) is limited in most patient and animal studies.
Conclusions:
- Converting enzyme inhibitors elicit significant renal effects in hypertension and heart failure.
- The precise mechanism, whether solely via angiotensin II reduction or involving other pathways like bradykinin or prostaglandins, requires further elucidation.
- Distinguishing between direct effects on angiotensin II formation and indirect actions remains a challenge.